To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC71091 | Napyradiomycin A1 |
Napyradiomycin A1 is one enantioselective compound of napyradiomycins. napyradiomycins are an intriguing family of halogenated natural products with activity against several tumor cell lines as well as some bacterial strains.
More description
|
|
| DC71071 | Lactonic sophorolipid |
Lactonic sophorolipid is a natural antimicrobial surfactant for oral hygiene. Lactonic sophorolipid, a potential anticancer agent, induces apoptosis in human HepG2 cells through the caspase-3 pathway.
More description
|
|
| DC71061 | INSCoV-614(1B) |
INSCoV-614(1B) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).
More description
|
|
| DC71060 | INSCoV-601I(1) |
INSCoV-601I(1) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).
More description
|
|
| DC71059 | INSCoV-600K(1) |
INSCoV-600K(1) is a potent inhibitor of Mpro (3CLpro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1).
More description
|
|
| DC71046 | FWM-3 |
FWM-3 is a potent SARS-CoV-2 NSP13 helicase inhibitor.
More description
|
|
| DC71039 | F-17 |
F-17 is a potential inhibitor of virulence factor. F-17 shows very significant inhibitory effect on biofilm, elastase, pyocyanin, and swarming motility. F-17 also shows a good binding effect on LasR and PqsR. F-17 has no obvious cytotoxicity.
More description
|
|
| DC71019 | Cladosporin |
Cladosporin is a fungal metabolite produced in good yield in the mycelium of Cladosporium cladosporioid. Cladosporin completely inhibits growth of severa dermatophytes on agar medium at a concentration of 75 μg/mL.
More description
|
|
| DC70981 | W13 |
W13 is a potent MsbA inhibitor. W13 is an ATPase stimulator with an EC50 of 5.5 µM.
More description
|
|
| DC70976 | STC314 |
STC314 is a small polyanion that interact electrostatically with histones. STC314 blocks disruption of lipid-bilayers by histones that inhibits the cytotoxic, platelet-activating and erythrocyte-damaging effects of histones. STC314 has anti-infective effects and can be uesd for sepsis research.
More description
|
|
| DC70965 | Cefcapene pivoxil |
Cefcapene pivoxil is an orally active cephalosporin antibiotic. It is a precursor agent that dissociates into free acid and then exerts antibacterial effect.
More description
|
|
| DC70964 | CBR-6672 |
CBR-6672 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.14 μM against Mtb.
More description
|
|
| DC70963 | CBR-3465 |
CBR-3465 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.16 μM against Mtb.
More description
|
|
| DC70959 | 6'-Sialyllactose sodium |
6'-Sialyllactose (sodium), a predominant milk oligosaccharide, reduces the internalisation of Pseudomonas aeruginosa in human pneumocytes.
More description
|
|
| DC70955 | Apigeninidin chloride |
Apigeninidin (Gesneridin) chloride, a 3‐deoxyanthocyanidin, is a fungal growth inhibitor. Apigeninidin chloride is a bioactive red biocolorant.
More description
|
|
| DC70953 | Lankacyclinone C |
Lankacyclinone C is a lankacidin C congener lacking the δ-lactone moiety, with antitumor activity.
More description
|
|
| DC70949 | GA-O-06 |
GA-O-06, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-06 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-06 displays a high antimicrobial activity against Gram-positive bacteria.
More description
|
|
| DC70948 | GA-O-02 |
GA-O-02, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-02 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-02 displays a high antimicrobial activity against Gram-positive bacteria.
More description
|
|
| DC70947 | G092 |
G092 is a potent inhibitor of MsbA. MsbA is an ABC transporter. Transmembrane ATP-binding cassette (ABC) transporters are crucial cellular machines that move molecules small and large across membranes. G092 has the potential for the research of antimicrobial drugs.
More description
|
|
| DC10450 | RN-18 Featured |
RN-18 is a selective inhibitor of virion infectivity factor (Vif) APOBEC interactions and HIV-1 replication.
More description
|
|
| DC10733 | Sutezolid (PNU-100480) Featured |
Sutezolid (PNU-100480) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis.
More description
|
|
| DC8063 | T-00127-HEV1 Featured |
T-00127-HEV1 is a novel potent phosphoinositide kinases (PIK) inhibitor,T-00127-HEV1 inhibited PI4KB activity with a higher specificity for than other PI kinases.
More description
|
|
| DC10265 | Tubercidin Featured |
Tubercidin, an adenosine analogue, is a nucleoside antibiotic. It is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis. This agent also exhibits antifungal and antiviral activities.
More description
|
|
| DC9828 | YYA-021 Featured |
YYA-021 is a small-molecule CD4 mimic that inhibits HIV entry, with high anti-HIV activity and low cytotoxicity.
More description
|
|
| DC11277 | Zoliflodacin(AZD0914) Featured |
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor.
More description
|
|
| DC70856 | UAMC-03011 |
UAMC-03011 is a potent anti-trypanosomal compound (IC50=0.63 uM, T. brucei).UAMC-03011 displays selectivity for Trypanosoma brucei over a panel including Trypanosoma cruzi, L.eishmania infantum, and Plasmodium falciparum (IC50>64 uM).
More description
|
|
| DC70797 | SRI-41897 |
SRI-41897 is a specific small molecule inhibitor of HIV-1 N-terminal region of NL4-3 Vpu (HIV-1 NL4-3 Vpu) with EC50 of 4.4 uM in the GaLV inhibition assays.SRI-41897 blocks Vpu-mediated modulation of CD4, BST-2/Tetherin and antibody dependent cell-mediated toxicity (ADCC).SRI-41897 rescues CD4 surface expression by 47% on infected TZM-GFP cells, also rescues the expression of CD4 and Tetherin in human peripheral blood mononuclear cells (PBMCs).
More description
|
|
| DC70757 | SBI-0797750 |
SBI-0797750 (SBI 0797750) is a potent, fully selective PfGluPho inhibitor with robust nanomolar activity against recombinant PfGluPho, PvG6PD, and P. falciparum blood-stage parasites.SBI-0797750 disturbs the cytosolic glutathione-dependent redox potential, as well as the cytosolic and mitochondrial H2O2 homeostasis of P. falciparum blood stages, at low nanomolar concentrations.SBI-0797750 does not harm red blood cell (RBC) integrity and phagocytosis and thus does not promote anemia.
More description
|
|
| DC70756 | SBI-0637142 |
SBI-0637142 is a potent Smac mimetic that preferentially targets BIRC2, latency-reversing agent (LRA), specifically and potently promote HIV-1 latency reversal activity.SBI-0637142 modestly induced HIV-1 latency ex vivo in CD4+ T cells from ART-suppressed aviremic HIV-infected patients as a single agent, showed robust activity when administered in combination with the HDACi panobinostat.SBI-0637142's latency reversal activity is dependent on the NIK-dependent NF-κB signaling.
More description
|
|
| DC70753 | S2C3 |
S2C3 is a small molecule HIV-1 fusion inhibitor, targets the membrane proximal external region (MPER) of HIV-1 envelope spike.S2C3 interacted with gp41-inter with an affinity of 2.0 uM.S2C3 has been shown to effectively block binding to the intact HIV-1 Env expressed on the cell surface by soluble CD4 but not by CD4 binding the sitedirected NAb VRC01, or the prefusion conformation-specific NAb PG16.S2C3 targets a site in the HIV-1 Env distinct from sites targeted by small-molecule entry inhibitors that have been identified so far.S2C3 could stabilize HIV-1 Env in the prefusion conformation, making it potentially useful in a vaccine preparation to reduce the conformational flexibility of Env.
More description
|
|